Individualized Pharmacokinetic Monitoring Results in Less Aminoglycoside‐Associated Nephrotoxicity and Fewer Associated Costs

Daniel S. Streetman; A N Nafziger; Christopher J. Destache; Joseph Bertino

doi:10.1592/phco.21.5.443.34490

April 1, 2001Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy

Individualized Pharmacokinetic Monitoring Results in Less Aminoglycoside‐Associated Nephrotoxicity and Fewer Associated Costs

View at Publisher

Ask AI

Bookmark

Share

Key Points

To evaluate the effect of individualized pharmacokinetic monitoring on aminoglycoside-associated nephrotoxicity rates and associated hospital costs.
Retrospective case-control study conducted across two teaching hospitals.
Analyzed 2,405 patients receiving aminoglycoside therapy dosed through individualized pharmacokinetic monitoring versus standard physician direction.
Individualized pharmacokinetic monitoring significantly reduced the incidence of nephrotoxicity compared to physician-directed dosing (7.9% vs. 13.2%, p = 0.02; adjusted OR 0.42, p = 0.002).
Risk factors for toxicity included age 50 years and older, high initial trough levels, longer duration of therapy, and concurrent use of piperacillin, clindamycin, or vancomycin, whereas female sex was protective.
Implementation of individualized pharmacokinetic monitoring resulted in an estimated cost reduction of $90,995 per 100 patients.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Retrospective case-control study shows individualized pharmacokinetic monitoring reduces nephrotoxicity and costs in patients receiving aminoglycosides, highlighting the value of targeted dosing.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Streetman et al. (2001) studied this question.

synapsesocial.com/papers/6a85c98f9df929a58fadadd8 https://doi.org/10.1592/phco.21.5.443.34490

View at Publisher

Ask AI

Bookmark

Share

Individualized Pharmacokinetic Monitoring Results in Less Aminoglycoside‐Associated Nephrotoxicity and Fewer Associated Costs

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Individualized Pharmacokinetic Monitoring Results in Less Aminoglycoside‐Associated Nephrotoxicity and Fewer Associated Costs

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

More related papers

More from Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy

Keep reading

More related papers

More from Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy